Cargando…

Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors

Prostate cancer (PCa) is the second most common cancer in men. Androgen deprivation therapy (ADT) leads to tumor involution and reduction of tumor burden. However, tumors eventually reemerge that have overcome the absence of gonadal androgens, termed castration resistant PCa (CRPC). Theories underly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mostaghel, Elahe A., Solomon, Keith R., Pelton, Kristine, Freeman, Michael R., Montgomery, R. Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261168/ https://www.ncbi.nlm.nih.gov/pubmed/22279565 http://dx.doi.org/10.1371/journal.pone.0030062

Ejemplares similares

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
por: Allott, Emma H., et al.
Publicado: (2018)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021)

The Response of the Prostate to Circulating Cholesterol: Activating Transcription Factor 3 (ATF3) as a Prominent Node in a Cholesterol-Sensing Network
por: Kim, Jayoung, et al.
Publicado: (2012)

Correction: The Response of the Prostate to Circulating Cholesterol: Activating Transcription Factor 3 (ATF3) as a Prominent Node in a Cholesterol-Sensing Network
por: Kim, Jayoung, et al.
Publicado: (2012)

Glucocorticoids and prostate cancer treatment: friend or foe?
por: Montgomery, Bruce, et al.
Publicado: (2014)

Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
por: Mostaghel, Elahe A
Publicado: (2014)

Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis
por: Mostaghel, Elahe A., et al.
Publicado: (2014)

Steroid hormone synthetic pathways in prostate cancer
por: Mostaghel, Elahe A.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Association of Prostate Cancer SLCO Gene Expression with Gleason Grade and Alterations Following Androgen Deprivation Therapy
por: Alsinnawi, Mazen, et al.
Publicado: (2019)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
por: Montgomery, Bruce, et al.
Publicado: (2010)

Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer
por: Zhou, Jianfu, et al.
Publicado: (2021)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis
por: Xu, Zhenyu, et al.
Publicado: (2020)

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer
por: Qian, Chen, et al.
Publicado: (2023)

Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: their relationships with tissue androgen levels.
por: Yang, Y., et al.
Publicado: (1993)

Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast
por: Yoda, Tomomi, et al.
Publicado: (2014)

Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer
por: Ganguly, Shinjini, et al.
Publicado: (2023)

Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
por: Maity, Sankar N., et al.
Publicado: (2016)

Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells.
por: Sherwood, E. R., et al.
Publicado: (1998)

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
por: Schweizer, Michael T., et al.
Publicado: (2016)

The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration
por: Atamanalp, S. Selcuk, et al.
Publicado: (2013)

Detecting predictive androgen receptor modifications in circulating prostate cancer cells
por: Steinestel, Julie, et al.
Publicado: (2015)

Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants
por: Minaiyan, Mohsen, et al.
Publicado: (2012)

Circulating Androgen Concentrations and Risk of Incident Heart Failure in Older Men: The Cardiovascular Health Study
por: Njoroge, Joyce N., et al.
Publicado: (2022)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
por: Marx, Sascha, et al.
Publicado: (2022)

Heated tobacco products and circulating high-density lipoprotein cholesterol concentrations
por: Hu, Huan, et al.
Publicado: (2022)

ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer
por: Freeman, Michael R., et al.
Publicado: (2019)

Role of OATP Transporters in Steroid Uptake by Prostate Cancer Cells in Vivo
por: Green, Sean, et al.
Publicado: (2016)

Mechanisms of Androgen-Independent Prostate Cancer
por: Saraon, Punit, et al.
Publicado: (2014)

Worsening of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in patients with prostate cancer after androgen deprivation therapy
por: Oka, Ryo, et al.
Publicado: (2018)

Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions
por: Mohammad, Osama S., et al.
Publicado: (2017)

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
por: Wadosky, Kristine M., et al.
Publicado: (2016)

Androgen receptor splice variants and prostate cancer: From bench to bedside
por: Wadosky, Kristine M., et al.
Publicado: (2017)

Does Changing Androgen Receptor Status during Prostate Cancer Development Impact upon Cholesterol Homeostasis?
por: Krycer, James Robert, et al.
Publicado: (2013)

Harnessing Solute Carrier Transporters for Precision Oncology
por: Nyquist, Michael D., et al.
Publicado: (2017)

Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol
por: Murray, Nigel P., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_c6e5clrh6thjfkbr62mg79dm9v